check_circleStudy Completed

Sunscreening Agents

18750-Sun Protection Factor Assay

Trial purpose

To evaluate the Sun Protection Factor (SPF) efficacy on human skin.

Key Participants Requirements

Sex

Both

Age

18 - 70 Years

  • - Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing.
    - Male or female
    - Aged between 18-70 years old.
    - Good health
    - Signed and dated Informed Consent Form
    - Signed and dated Health Insurance Portability and Accountability Authorization (HIPAA) Form
    - An unambiguous MED or MPPD (Minimal Persistent Pigment Darkening Dose)


  • - Subjects on test at any other research laboratory or clinic.
    - Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light.
    - PRe-existing dermatologic conditions which have been diagnoses by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study.
    - Pre-existing other medical conditions (e.g. adult asthma. diabetes).
    - Treatment with antihistamines or corticosteroids within one week prior to initiation of the test.
    - Treatment with antibiotics within two weeks prior to initiation of the test
    - Chronic medication which could affect the results of the study.
    - Known pregnant or nursing women.

Trial summary

Enrollment Goal
10
Trial Dates
March 2016 - March 2016
Phase
N/A
Could I Receive a placebo
No
Products
BAY987517
Accepts Healthy Volunteer
Yes

Where to participate

StatusInstitutionLocation
Completed
Union, 07083, United States

Primary Outcome

  • Minimal Erythema Dose(MED)
    date_rangeTime Frame:
    Up to 15 minites
    enhanced_encryption
    Safety Issue:
    No
  • Minimal Persistent Pigment Darkening Dose (MPPD)
    date_rangeTime Frame:
    Up to 15 minites
    enhanced_encryption
    Safety Issue:
    No

Trial design

Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
N/A
Blinding
Open Label
Assignment
Single Group Assignment
Trial Arms
1